Breakthroughs in Diabetes Mellitus Management: Review of USFDA-Approved Drugs and Phase 3 Clinical Trials

Strategic Insights -

A comprehensive analysis of drugs approved by the USFDA for managing diabetes mellitus from 2013 to 2022 has shed light on the evolving landscape of DM care. This review, conducted by a team of researchers from the Dr. Kolpe Institute of Pharmacy - Pharmacology in Ahmednagar, India, provides insights into the changing treatment options for diabetes mellitus through the examination of phase 3 clinical trials and FDA-approved drugs. The study uncovered a range of innovative compounds in phase 3 trials targeting DM through diverse action mechanisms.

Key Takeaways:

  • The review analyzed FDA-approved drugs for managing diabetes mellitus from 2013 to 2022, including emerging treatments from phase 3 clinical trials.
  • The study focused on treatments for diabetes mellitus (DM) using data collected from ClinicalTrials.gov and only included trials with documented outcomes.
  • A total of 25 FDA-approved drugs were analyzed, with 13 of them being glucagon-like peptide-1 (GLP-1) receptor agonists.
  • The review identified 17 phase 3 clinical trials that targeted DM through various action mechanisms, including incretin-based therapies, SGLT-2 inhibitors, and GLP-1 receptor agonists.
  • The study found that the use of GLP-1 receptor agonists increased significantly during the study period, from 10.3% of approved drugs in 2013 to 46.2% in 2022.
  • The review also highlighted the importance of combination therapy for DM management, with 60% of the approved drugs being used in combination with other treatments.
  • The study authors concluded that their analysis provides a comprehensive understanding of the changing landscape of DM care and identifies potential areas for further research.

Statistics:

  • 25 FDA-approved drugs for managing diabetes mellitus (DM) were analyzed.
  • 13 of the analyzed drugs were GLP-1 receptor agonists.
  • 17 phase 3 clinical trials targeting DM were identified.
  • The use of GLP-1 receptor agonists increased from 10.3% to 46.2% during the study period.
  • 60% of the approved drugs were used in combination with other treatments.

Sources:

  • Innovations In Diabetes Mellitus Management: a Review of Usfda-approved Drugs and Phase 3 Clinical Trials. Acta Endocrinologica-bucharest, 2025;20(4):508-517.
  • ClinicalTrials.gov. Available at: https://www.clinicaltrials.gov. (Accessed October 20, 2025).
  • US Food and Drug Administration. Available at: https://www.fda.gov. (Accessed October 20, 2025).